Vitamin K2 (MK-7)
Last reviewed
Vitamin K2 in the MK-7 form activates the proteins that route calcium into bone rather than soft tissue and vasculature, and supports collagen matrix quality relevant to hEDS. It works synergistically with D3 to reduce the soft tissue calcification risk that long-term D3 supplementation can otherwise drive. ZebraThrive uses 100 mcg MK-7 daily.
At a Glance
Daily Dose
100 mcg MK-7 daily
Key Benefits
How It Works
Vitamin K2 activates Matrix Gla Protein (MGP), which binds calcium in the bloodstream and limits its deposition in arteries and soft tissues, directing it toward bone instead. This is critical when taking D3, which increases calcium absorption.
In connective tissue, K2 activates osteocalcin, enhancing collagen matrix quality. Research shows it increases collagen synthesis via the SXR pathway and organizes collagen fibrils. Regarding mast cells, historical studies demonstrated that menaquinone significantly inhibits degranulation in both models and human basophils, with clinical effectiveness shown in asthma trials.
What the Research Shows
Historical research demonstrates significant stabilizing properties.
Decreases MMP-3 levels, protecting the collagen matrix.
RCT, n=84
100 μg/day MK-7 significantly decreased MMP-3 and disease activity markers.
Long-term trials demonstrate improved vascular elasticity and reduced stiffness.
3-year RCT, n=244
Significantly decreased arterial stiffness and improved vascular elasticity.
Addressing the Triad
Tailored benefits for complex conditions
K2 has documented mast cell stabilization activity - the original work goes back to Kimura 1975 (rat mesenteric mast cells, human basophils from asthma patients) showing K2 inhibited both IgE-mediated and antibody-induced degranulation. A 2021 pediatric atopic dermatitis study (Zhang) confirmed K2 suppresses IL-17A, IL-10, and TNF-α through MAPK/ERK inhibition. The mechanism is real but understudied in MCAS populations specifically. We position K2 as secondary mast cell support alongside the dedicated stabilizers. Sourcing matters: synthetic or chickpea-fermented MK-7, not natto-derived, because natto's biogenic amines are a documented MCAS trigger.
For hEDS, K2's primary relevance is bone and connective tissue: K2 activates matrix Gla protein (MGP) and osteocalcin - proteins that direct calcium to where it's structurally needed. EDS populations show higher fracture rates that correlate with both D and K status. K2 also inhibits MMP-3 (a connective tissue-degrading enzyme) at 100 mcg/day in clinical trials in rheumatoid arthritis patients. Studies in pseudoxanthoma elasticum (a different connective tissue disorder) were negative, so we don't overclaim - but the protein activation mechanism is well-established and the safety profile across 40+ trials is favorable.
K2's POTS relevance is mostly indirect, working through cardiovascular maintenance. Activating matrix Gla protein keeps calcium from depositing in vascular smooth muscle - important for long-term vascular function. Some animal studies suggest K2 supports endothelial responsiveness. There's no direct POTS clinical evidence - K2 is not a primary autonomic intervention. The reason it's in the formulation is mostly the D3 pairing (D3 raises calcium absorption, K2 directs where calcium goes) and the broader bone-and-connective-tissue maintenance work. For POTS specifically, the bigger benefits come from other ingredients in the stack.
Why We Chose This Form
We use MK-7 (menaquinone-7) specifically, not MK-4 or short-chain forms. MK-7 has a half-life of around 3 days (compared to MK-4's roughly 1 hour), which means a single daily dose maintains steady tissue concentrations. The 100 mcg dose is within the clinical trial range (45-720 mcg daily, up to 24 months in human studies). Sourcing matters for MCAS: we specify synthetic or chickpea-fermented MK-7, not natto-derived. Natto is heavily fermented and a documented MCAS trigger - the same molecule from a non-natto source delivers the same benefits without the histamine load.
Form Comparison
MK-7 (Menaquinone-7)
72-hour half-life; once-daily dosing; 10x better bioavailability
MK-4 (Menaquinone-4)
6-hour half-life; requires multiple doses; poor absorption
Chickpea-fermented or synthetic MK-7 source
Soy-free, no natto-derived biogenic amines; descriptive of our sourcing
Safety & Interactions
Potential Side Effects
Excellent safety profile. Does not increase bleeding risk at standard doses.
Drug Interactions
CONTRAINDICATED with warfarin/vitamin K antagonists. No known issues with beta-blockers, fludrocortisone, or MCAS stabilizers.
Excipients to Avoid
- Povidone
- Sodium lauryl sulfate
- PEG
- Magnesium stearate
Safe Excipients
- HPMC capsules
- Rice flour
- Cellulose
- Ascorbyl palmitate
Absolutely avoid if on warfarin. Coagulation safety confirmed at 90μg doses in healthy volunteers.
How to Start
| Protocol Step | Suggested Dosage | Key Notes |
|---|---|---|
| Weeks 1-2 | 50 mcg daily | Conservative start |
| Week 3+ | 100 mcg daily | Standard therapeutic dose |
"Take with fat. Vascular benefits observed over 3+ months; optimal bone/calcium benefits take longer."
State of the Evidence
No direct evidence in hEDS, POTS, or MCAS populations. Mast cell evidence is historical (1975) and requires modern replication. No studies exist on heart rate or autonomic markers.
- [1]Mast cell stabilization by menaquinonePMID: 126001
Kimura I et al. (1975)
- [2]MK-7 in rheumatoid arthritis RCT decreases MMP-3PMID: 26073022
Abdel-Rahman MS (2015)
- [3]3-year MK-7 arterial stiffness trialPMID: 25694037
Knapen MH et al. (2015)
- [4]MK-7 vs MK-4 bioavailability comparisonPMID: 23140417
Sato T et al. (2012)
- [5]Coagulation safety with MK-7PMID: 34115006
Ren et al. (2021)
- [6]Kimura I et al.PMID: 51576
Common Questions
Written by Ken Chapman, Founder of ZebraThrive. Reviewed and last updated .